IL2 and lung disorder: Here, we prospectively compared the long-term therapeutic efficacy of four outpatient combination regimens: arm A (sc-IL-2, sc-IFN-α2a, po-13cRA) and arm B (arm A plus inhaled-IL-2) in patients with pulmonary disease, and arm C (arm A plus iv-5-FU) and arm D (arm A plus po-Capecitabine) in all others.